Literature DB >> 7641335

Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.

S K Yao1, S Akhtar, T Scott-Burden, J C Ober, P Golino, L M Buja, W Casscells, J T Willerson.   

Abstract

BACKGROUND: Nitric oxide (NO), an endothelium-derived relaxing factor, plays an important role in regulating platelet activation. We evaluated the effect of NO in a canine model of intracoronary thrombosis, thrombolysis, and reocclusion. METHODS AND
RESULTS: Before thrombosis was induced, 34 anesthetized dogs were treated with a continuous intracoronary infusion of saline (n = 8); NG-nitro-L-arginine (L-NNA, n = 8), an inhibitor of NO synthetase; L-arginine (n = 7), the precursor for NO; or sodium nitroprusside (SNP, n = 11), an NO donor. Ten minutes after the infusion was begun, an electric current of 150 microA was applied to the endothelium of coronary arteries to induce thrombosis. Occlusive thrombi developed in all dogs in the saline group (38 +/- 4 minutes) and the L-NNA group (30 +/- 6 minutes), in 6 of 7 dogs in the L-arginine group (81 +/- 18 minutes), and in 6 of 11 dogs in the SNP group (102 +/- 21 minutes) (P < .01). The time to thrombus was prolonged by L-arginine (P < .05) and SNP (P < .01). After 3 hours of thrombus formation in coronary arteries, tissue plasminogen activator and heparin were administered intravenously. Thrombi were lysed in 4 (of 8) dogs in the saline group (71 +/- 8 minutes), in 4 (of 8) dogs in the L-NNA group (72 +/- 8 minutes), in 4 (of 6) dogs in the L-arginine group (50 +/- 14 minutes), and in 4 (of 6) dogs in the SNP group (49 +/- 11 minutes) (P > .05). After thrombolysis, coronary artery reocclusion developed in all reperfused dogs in the saline group (30 +/- 8 minutes) and in the L-NNA group (48 +/- 12 minutes), in 3 (of 4) reperfused dogs in the L-arginine group (123 +/- 26 minutes), and in 3 (of 4) reperfused dogs in the SNP group (128 +/- 19 minutes) (P < .01). The ex vivo platelet aggregation induced by collagen was inhibited after in vivo treatment with L-arginine or SNP.
CONCLUSIONS: Increasing NO production or giving an NO donor may inhibit platelet aggregation and delay intracoronary thrombus formation and reocclusion after thrombolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641335     DOI: 10.1161/01.cir.92.4.1005

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest.

Authors:  E A Konorev; J Joseph; M M Tarpey; B Kalyanaraman
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Isolation and study of insulin activated nitric oxide synthase inhibitory protein in acute myocardial infarction subjects.

Authors:  Udayan Ray; Gausal A Khan; Kushal Chakraborty; Shyamali Basuroy; Sharmistha Chakraborty Patra; Gannareddy Girish; G Bhattacharya; Asru K Sinha
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

3.  Rheolytic pharmacomechanical thrombectomy in experimental chronic deep vein thrombosis: effect of L-arginine on thrombogenicity and endothelial vasomotor function.

Authors:  Peter H Lin; Tamuru Okada; James L Steinberg; Wei Zhou; Hosam F El Sayed; Anish Rawat; Panos Kougias; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

4.  Effects of propofol on myocardial ischemia-reperfusion injury in rats with type-2 diabetes mellitus.

Authors:  Ying Wang; Xiuru Qi; Chunliang Wang; Danning Zhao; Hongjie Wang; Jianxin Zhang
Journal:  Biomed Rep       Date:  2016-11-09

5.  The thrombolytic effect of aspirin in animal model.

Authors:  Soumendra K Karmohapatra; Nighat N Kahn; Asru K Sinha
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 2.300

6.  Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model.

Authors:  J M Waugh; M Kattash; J Li; E Yuksel; M D Kuo; M Lussier; A B Weinfeld; R Saxena; E D Rabinovsky; S Thung; S L Woo; S M Shenaq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

7.  Gene therapy for atherosclerosis and atherosclerosis-related diseases.

Authors:  T Pakkanen; S Ylä-Herttuala
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.967

8.  Control of systemic inflammation through early nitric oxide supplementation with nitric oxide releasing nanoparticles.

Authors:  Alexander T Williams; Cynthia R Muller; Krianthan Govender; Mahantesh S Navati; Adam J Friedman; Joel M Friedman; Pedro Cabrales
Journal:  Free Radic Biol Med       Date:  2020-10-02       Impact factor: 7.376

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.